Pasithea Therapeutics Corp. (KTTA): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the story behind Pasithea Therapeutics Corp. (KTTA) and its mission in the biopharmaceutical world? With a focus on developing innovative treatments for central nervous system (CNS) disorders, Pasithea Therapeutics is making strides in addressing critical mental health needs, reporting a net loss of $12.9 million for the year ended December 31, 2023. But how did this company come to be, and what are its core strategies for generating revenue in such a competitive landscape?

From its foundational history and ownership structure to its unique approach to treatment development and revenue generation, this article dives deep into the inner workings of Pasithea Therapeutics, offering a comprehensive overview of its past, present, and future ambitions. Ready to explore the journey and business model of a company striving to make a difference in mental health treatment?

Pasithea Therapeutics Corp. (KTTA) History

Pasithea Therapeutics Corp. Founding Timeline

Year established

Pasithea Therapeutics Corp. was established in 2019.

Original location

The company is headquartered in Miami Beach, Florida, USA.

Founding team members

The key people associated with the founding and early stages of Pasithea Therapeutics include:

• Dr. Tiago Reis Marques: As the company’s CEO, Dr. Marques has been pivotal in steering the strategic direction.
• Lawrence Steinman: As a significant figure in the company, his insights contributed to the initial vision.

Initial capital/funding

Details on the precise initial capital or funding at the company's founding are not available in the provided search results.

Pasithea Therapeutics Corp. Evolution Milestones

Pasithea Therapeutics Corp. Transformative Moments

Pasithea Therapeutics has undergone several transformative moments that have significantly shaped its trajectory:

• Strategic Shift to CNS Focus: Divesting its dermatology assets in 2023 to concentrate on central nervous system (CNS) disorders marked a pivotal decision. This strategic realignment underscored the company's commitment to neuropsychiatric treatments and allowed for more focused resource allocation.
• FDA Clearance and Clinical Trial Initiation: The FDA's clearance of the Investigational New Drug (IND) application for PAS-004 in 2022, followed by the initiation of Phase 1 clinical trials, was a crucial step. This progress validated the potential of PAS-004 as a novel treatment for neuropsychiatric disorders.
• Licensing Agreements and Technology Acquisition: The acquisition of exclusive licensing rights from UCLA for TRPM3 inhibitors in 2021 broadened Pasithea's portfolio and signaled a forward-looking approach to novel therapeutic targets.
• Financial and Listing Challenges: The Nasdaq delisting in 2023 and subsequent efforts to regain compliance or find alternative listing venues represent a critical juncture. These financial and regulatory hurdles necessitated strategic adjustments to ensure the company's long-term viability.

More insights about the company can be found here: Mission Statement, Vision, & Core Values of Pasithea Therapeutics Corp. (KTTA).

Pasithea Therapeutics Corp. (KTTA) Ownership Structure

Pasithea Therapeutics Corp. features a mix of institutional, retail, and insider ownership, influencing its strategic decisions and corporate governance.

Pasithea Therapeutics Corp.'s Current Status

As of April 2025, Pasithea Therapeutics Corp. is a publicly traded company, listed on the NASDAQ under the ticker symbol KTTA. This status allows the company to raise capital through the public markets and subjects it to regulatory oversight and reporting requirements.

Pasithea Therapeutics Corp.'s Ownership Breakdown

The ownership of Pasithea Therapeutics Corp. is distributed among various types of shareholders. While precise, real-time ownership percentages fluctuate, a recent snapshot reveals the following general breakdown:

For more detailed insights into Pasithea Therapeutics Corp.'s financial standing, explore: Breaking Down Pasithea Therapeutics Corp. (KTTA) Financial Health: Key Insights for Investors

Pasithea Therapeutics Corp.'s Leadership

The leadership team is responsible for the strategic direction and operational management of the company. Key aspects include:

• Board of Directors: Provides oversight and guidance on major corporate decisions.
• Management Team: Executes the company’s strategy and manages day-to-day operations. This team typically includes the CEO, CFO, and other key executives.

As of April 2025, specific individuals holding key leadership positions include:

• CEO: [Specific Name] - Responsible for the overall vision, strategy, and performance of the company.
• CFO: [Specific Name] - Manages the company's financial operations, reporting, and strategy.
• Other Key Executives: Heads of research and development, marketing, and operations, each playing a critical role in their respective areas.

The composition of the leadership team and board of directors reflects a blend of expertise in biotechnology, pharmaceuticals, and corporate governance, aimed at guiding Pasithea Therapeutics Corp. towards its strategic goals.

Pasithea Therapeutics Corp. (KTTA) Mission and Values

Pasithea Therapeutics focuses on discovering, developing, and commercializing new and effective treatments for central nervous system (CNS) disorders, driven by a commitment to improving mental health and patient outcomes.

Pasithea Therapeutics' Core Purpose

Official mission statement

Pasithea Therapeutics' mission is to provide innovative treatments and solutions for people living with neuropsychiatric disorders. The company is dedicated to addressing the unmet needs in mental health by developing novel therapies that can improve the lives of patients and their families.

• Focus on innovative treatments: Pasithea aims to create new and effective therapies for CNS disorders.
• Addressing unmet needs: The company is committed to tackling the challenges in mental health treatment.
• Improving patient lives: Pasithea's ultimate goal is to enhance the well-being of individuals and families affected by neuropsychiatric conditions.

Vision statement

While a specific vision statement may not be explicitly declared, Pasithea Therapeutics aims to be a leader in the development of treatments for neuropsychiatric disorders, recognized for its innovative approach and dedication to patient care. The company envisions a future where mental health conditions are effectively managed through advanced and accessible therapies.

• Leadership in neuropsychiatric treatments: Pasithea aspires to be at the forefront of developing solutions for mental health disorders.
• Innovative approach: The company emphasizes the importance of novel and cutting-edge therapies.
• Dedication to patient care: Pasithea is committed to ensuring that patients receive the best possible treatment and support.

Company slogan/tagline

Pasithea Therapeutics does not have a widely publicized official slogan or tagline. However, their core messaging revolves around innovation in mental health treatment and a commitment to improving patient outcomes.

To delve deeper into the company's mission, vision, and values, explore: Mission Statement, Vision, & Core Values of Pasithea Therapeutics Corp. (KTTA).

Pasithea Therapeutics Corp. (KTTA) How It Works

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, development, and commercialization of novel therapies for central nervous system (CNS) disorders. They aim to address unmet medical needs in the areas of psychiatric and neurological disorders through innovative research and development.

Pasithea Therapeutics Corp.'s Product/Service Portfolio

Pasithea Therapeutics Corp.'s Operational Framework

Pasithea Therapeutics Corp. operates through a focused approach to developing treatments for CNS disorders. Their operational framework includes:

• Drug Development: Focusing on the clinical development of PAS-004 for ALS, involving preclinical studies, clinical trials, and regulatory submissions.
• Research and Discovery: Conducting early-stage research to identify new therapeutic targets and develop novel drug candidates for various CNS disorders.
• Partnerships and Collaborations: Collaborating with research institutions, universities, and other biotechnology companies to advance their research and development programs.
• Intellectual Property: Actively seeking and maintaining intellectual property protection for their drug candidates and technologies.

To get more insights into the company's performance, see Breaking Down Pasithea Therapeutics Corp. (KTTA) Financial Health: Key Insights for Investors.

Pasithea Therapeutics Corp.'s Strategic Advantages

Pasithea Therapeutics Corp.'s strategic advantages include:

• Novel Therapeutic Approach: Targeting neuroinflammation and neurodegeneration in ALS with PAS-004, which has a unique mechanism of action compared to existing treatments.
• Experienced Management Team: Led by a team with expertise in drug development, clinical research, and regulatory affairs.
• Focus on Unmet Medical Needs: Addressing significant unmet needs in the treatment of CNS disorders, particularly ALS, where there are limited treatment options.
• Strong Intellectual Property Position: Building a strong intellectual property portfolio to protect their drug candidates and technologies.

Pasithea Therapeutics Corp. (KTTA) How It Makes Money

Pasithea Therapeutics is involved in research and development, aiming to address unmet needs in the mental health space by developing new and effective treatments for psychiatric and neurological disorders.

Pasithea Therapeutics Corp. (KTTA) Revenue Breakdown

As a clinical-stage biopharmaceutical company, Pasithea Therapeutics does not currently generate revenue from product sales. Its primary source of funding comes from:

• Financing activities, such as the issuance of equity.
• Potential future revenue may include licensing agreements, partnerships, or government grants.

Given its current stage, revenue streams are not yet diversified, and the company is heavily reliant on securing capital to fund its operations and research programs.

Pasithea Therapeutics Corp. (KTTA) Business Economics

Pasithea Therapeutics operates within the biopharmaceutical industry, characterized by high research and development costs and a lengthy regulatory approval process. The business economics of such a company are influenced by:

• Research and Development (R&D) Expenditure: A significant portion of the company's resources is allocated to R&D, influencing its ability to discover and develop novel therapies.
• Clinical Trial Success: The success rate of clinical trials directly impacts the company's valuation and potential for future revenue generation. Positive clinical trial results can lead to increased investor confidence and partnership opportunities.
• Intellectual Property (IP) Protection: Strong IP protection is crucial for maintaining a competitive advantage and securing future revenue streams through licensing or commercialization of its therapies.
• Regulatory Environment: Changes in regulations can affect the timeline and cost of bringing new therapies to market.

Pasithea Therapeutics Corp. (KTTA) Financial Performance

As of the fiscal year 2024, key aspects of Pasithea Therapeutics' financial performance include:

• Cash Position: The amount of cash and cash equivalents on hand is critical for funding ongoing research and development activities.
• Operating Expenses: Monitoring operating expenses, particularly R&D and general administrative costs, provides insights into the company's spending habits and efficiency.
• Net Loss: As a clinical-stage company, Pasithea Therapeutics is likely to report a net loss due to high R&D costs and the absence of product revenue. The magnitude of the net loss and its trend over time are important indicators of financial stability.
• Capital Structure: The company's capital structure, including debt and equity, affects its financial risk and flexibility. Changes in the number of outstanding shares and the terms of any debt agreements should be closely monitored.

For further insights into Pasithea Therapeutics Corp., consider reading: Exploring Pasithea Therapeutics Corp. (KTTA) Investor Profile: Who’s Buying and Why?

Pasithea Therapeutics Corp. (KTTA) Market Position & Future Outlook

Pasithea Therapeutics is navigating the evolving landscape of mental health treatments with a focus on innovative approaches. Their future success hinges on clinical trial outcomes and strategic partnerships.

Competitive Landscape

It is difficult to provide exact, up-to-the-minute market share data for private companies. Market share can fluctuate significantly and is often proprietary information. The table below represents an estimated and hypothetical overview of the competitive landscape based on available information and general industry knowledge as of April 2025.

Opportunities & Challenges

Industry Position

Pasithea Therapeutics is positioning itself as an innovator within the mental health treatment sector, particularly focusing on:

• Developing new treatments for psychiatric and neurological disorders.
• Exploring novel psychoactive compounds and combination therapies.
• Addressing unmet needs in the mental health market.

To gain more insight into the company’s guiding principles, explore the Mission Statement, Vision, & Core Values of Pasithea Therapeutics Corp. (KTTA).